Pipeline
| NAME | ORIGINATOR | INDICATION | DEVELOPMENT STATUS |
|---|---|---|---|
| Zanipress® / Zanitek® | Recordati | Hypertension (lercanidipine + enalapril) | Launched in the RMS (Germany) MRP completed |
| rupatadine | Uriach | Rhinitis, allergic, seasonal / perennial urticaria | Approved |
| fentanyl patch | Lavipharm | Moderate to severe chronic pain | Filed in the RMS (UK) |
| prulifloxacin | Nippon Shinyaku / Angelini | Infection, respiratory tract, urinary tract | Filed |
| silodosin | Kissei | Benign prostatic hyperplasia | Phase III |
| pitavastatin | Kowa | Hyperlipidemia, general | Phase III |
| 2 new lercanidipine combinations |
Recordati | Hypertension | Phase II |
| lercanidipina MR | Different technology platforms | Hypertension, general | Formulation / Phase II |
| REC 0422 | Recordati | Overactive bladder and incontinence | Preclinical |
| REC 1819 | Recordati | Overactive bladder and incontinence | Preclinical |
Pipeline – Drugs for rare diseases
| NAME | ORIGINATOR | INDICATION | DEVELOPMENT STATUS |
|---|---|---|---|
| Carbaglu® | Orphan Europe (Recordati) |
NAGS deficiency | Approved in EU Filed in US |
| Carbaglu® | Orphan Europe (Recordati) |
Organic acidaemias | Pre-registration in EU |
| Vedrop® | Orphan Europe (Recordati) |
Vitamin E deficiency in cystic fibrosis and chronic cholestasis |
Filed with EMEA |
| Infasurf® | Ony | Calf derived surfactant for RDS | Pre-filing |
| Stanate® | Rockefeller U. / InfaCare | Neonatal jaundice, hyperbilirubinemia | Phase II / III |
| Cystagon® | Mylan | Other indication unrelated to nephropathic cystinosis | Phase II / III |
| Cystadrops® | Orphan Europe (Recordati) |
Ocular cystinosis | Phase II |
| Normosang® | Orphan Europe (Recordati) |
Hepatic porphyria | Approved in EU Pre-registration in US |
